| Demographics . | n = 47 . |
|---|---|
| Median age, yr (range) | 58 (34–70) |
| Gender, n | 28 male; 19 female |
| Stage | |
| Stage III | 3 (6%) |
| Stage IV | 44 (94%) |
| ECOG PS | |
| 0 | 35 (74%) |
| 1 | 11 (23%) |
| 2 | 1 (2%) |
| Treatment received | |
| R-CHOP | 7 (15%) |
| R-HyperCVAD | 15 (32%) |
| R-CHOP/R-DHAP | 23 (49%) |
| Dose-adjusted R-EPOCH | 1 (2%) |
| R-Bendamustine | 1 (2%) |
| Response to immunochemotherapy | |
| PR | 5 (11%) |
| CR | 42 (89%) |
| MIPI | |
| Low risk | 26 (55%) |
| Intermediate risk | 15 (32%) |
| High risk | 6 (13%) |
| Ki-67 | |
| ≥30% | 18 (38%) |
| ≤30% | 22 (47%) |
| Unknown | 7 (15%) |
| B-MIPI | |
| Low risk | 8 (17%) |
| Intermediate risk | 20 (43%) |
| High risk | 12 (26%) |
| Unknown | 7 (15%) |
| Demographics . | n = 47 . |
|---|---|
| Median age, yr (range) | 58 (34–70) |
| Gender, n | 28 male; 19 female |
| Stage | |
| Stage III | 3 (6%) |
| Stage IV | 44 (94%) |
| ECOG PS | |
| 0 | 35 (74%) |
| 1 | 11 (23%) |
| 2 | 1 (2%) |
| Treatment received | |
| R-CHOP | 7 (15%) |
| R-HyperCVAD | 15 (32%) |
| R-CHOP/R-DHAP | 23 (49%) |
| Dose-adjusted R-EPOCH | 1 (2%) |
| R-Bendamustine | 1 (2%) |
| Response to immunochemotherapy | |
| PR | 5 (11%) |
| CR | 42 (89%) |
| MIPI | |
| Low risk | 26 (55%) |
| Intermediate risk | 15 (32%) |
| High risk | 6 (13%) |
| Ki-67 | |
| ≥30% | 18 (38%) |
| ≤30% | 22 (47%) |
| Unknown | 7 (15%) |
| B-MIPI | |
| Low risk | 8 (17%) |
| Intermediate risk | 20 (43%) |
| High risk | 12 (26%) |
| Unknown | 7 (15%) |
Data are presented as n (%) unless specified otherwise. ECOG PS, Eastern Cooperative Oncology Group performance status; R-HyperCVAD, rituximab, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; R-DHAP, rituximab, dexamethasone, cytarabine, and cisplatin; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin; PR, partial response; CR, complete response.